Eribulin mesylate (
eribulin) is a nontaxane microtubule inhibitor approved in Japan for treating
soft tissue sarcoma irrespective of histological subtypes. Thus, our department routinely uses
eribulin to treat any histological subtype of
sarcoma for patients who have experienced
disease progression during standard
therapy. However, evidence on the efficacy of
eribulin in treating
sarcomas that are neither
liposarcoma nor
leiomyosarcoma is limited. Recently, we encountered a case of a heavily pretreated cardiac
angiosarcoma that responded well to
eribulin treatment. The patient was a 34-year-old Japanese woman with advanced
angiosarcoma, who had been pretreated heavily using several lines of
chemotherapy.
Eribulin was administered as the eighth line of treatment and the dose was adjusted because of grade 4
neutropenia. After three cycles of treatment, contrast-enhanced computed tomography showed a partial
tumor response, which was sustained for ~4 months. This case suggests that
eribulin may be a potential therapeutic option for
angiosarcoma. Further studies are needed to confirm the benefit of
eribulin for patients with
angiosarcoma and to establish predictive markers for
eribulin sensitivity.